ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: SA-PO1179

Role of Histone Deacetylase-1 in Interstitial Fibrosis

Session Information

Category: CKD (Non-Dialysis)

  • 2103 CKD (Non-Dialysis): Mechanisms

Author

    Group or Team Name

    • Kaitlyn Aldaz. The University of Alabama at Birmingham, Birmingham, AL.
    Background

    Acute kidney injury can lead to chronic kidney disease through myofibroblast secretion of extracellular matrix (ECM) leading to interstitial fibrosis and a loss of kidney function. We reported that following ischemia-reperfusion-injury (IRI), the transcriptional regulator, histone deacetylase-1 (HDAC1) is increased in the kidney. Inhibition of HDAC1 reduced IRI-mediated interstitial fibrosis. We hypothesized that fibroblast HDAC1 was profibrotic and developed an inducible HDAC1 fibroblast knockout (KO) mouse.

    Methods

    Fibroblast HDAC1 was deleted in adulthood, and the male mice underwent sham or bilateral IRI (2-weeks of reperfusion) surgeries.

    Results

    Plasma creatinine was significantly elevated in control IRI mice (0.20 ± 0.02 mg/dl) compared to sham (0.12 ± 0.001) or KO mice (sham = 0.13 ± 0.009, IRI = 0.14 ± 0.02, PGenotype = 0.2, PSurgery = 0.02, Pinteraction = 0.03) suggesting that the KOs had better kidney function. Interstitial sirius red staining, α−smooth muscle actin (αsma), and fibronectin expression was increased in the control IRI mice compared to shams or KO mice. Next, Normal Rat Kidney 49 Fibroblast cells transfected with human HDAC1 or empty vectors. Injury was simulated by treatment of cells with TGF-β1, a master regulator of myofibroblast activation. Overexpression of HDAC1 did not significantly affect myofibroblast markers (αsma, fibronectin). TGF-β1 treatment led to myofibroblast activation, regardless of HDAC1 level. Interestingly, HDAC1 was found to suppress p53 expression, a master regulator of the cell cycle.

    Conclusion

    Together, our data suggest that fibroblast HDAC1 is profibrotic, but it may be through regulation of myofibroblast cell cycle, rather than direct effects on ECM secretion.